Why the study?
Sex differences in repolarization are known, but their impact on ECG repolarization markers for the telemonitoring of chronic heart failure patients remained unstudied.
Do ECG repolarization markers predict 30-day mortality and decompensation differently in men versus women with chronic heart failure?
Do ECG repolarization markers predict 30-day mortality and decompensation differently in men versus women with chronic heart failure?
The standard deviation of the T peak to T end interval (TeSD) is a reliable marker for predicting 30-day mortality and heart failure worsening in both men and women, though sex-specific cutoffs may be required.
Te SD may aid CHF telemonitoring similarly in both sexes; leaves open need for sex-specific cutoffs and prospective validation.
Aging and chronic heart failure (CHF) are responsible for the temporal inhomogeneity of the electrocardiogram (ECG) repolarization phase. Recently, some short period repolarization–dispersion parameters have been proposed as markers of acute decompensation and of mortality risk in CHF patients. Some important differences in repolarization between sexes are known, but their impact on ECG markers remains unstudied. The aim of this study was to evaluate possible differences between men and women in ECG repolarization markers for the telemonitoring of CHF patients. Method: 5 min ECG recordings were collected to assess the mean and standard deviation (SD) of the following variables: QT end (QTe), QT peak (QTp), and T peak to T end (Te) in 215 decompensated CHF (age range: from 49 to 103 years). Thirty-day mortality and high levels of NT-pro BNP (<75 percentile) were considered markers of decompensated CHF. Results: A total of 34 patients (16%) died during the 30-day follow-up, without differences between sexes. Women showed a more preserved ejection fraction and higher LDL and total cholesterol levels. Among female patients, implantable cardioverter devices, statins, and antiplatelet agents were less used. Data for Te mean showed increased values among deceased men and women compared to survival, but TeSD was shown to be the most reliable marker for CHF reacutization in both sexes. Conclusion: TeSD could be considered a risk factor for CHF worsening and complications for female and male patients, but different cut offs should be taken into account. (ClinicalTrials.gov number, NCT04127162.)
No takes yet. Share an insight, caveat, or question.
Moscucci et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: